These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11679560)

  • 41. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.
    Hoogkamp-Korstanje JA; Roelofs-Willemse J
    J Antimicrob Chemother; 2000 Jan; 45(1):31-9. PubMed ID: 10629010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
    Hong SG; Moland ES; Wickman PA; Black JA; Hossain A; Hanson ND; Thomson KS
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1512-4. PubMed ID: 17220419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
    Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Activities of antimicrobial agents against 8,474 clinical isolates obtained from 37 medical institutions during 2000 in Japan].
    Yamaguchi K; Ohno A; Kashitani F; Iwata M; Kanda M; Tsujio Y; Sugiyama T; Toyoshima S; Kato J; Watanabe N; Kaku M; Kanemitsu K; Kunishima H; Kawaguchi H; Okada J; Shimoyama N; Igari J; Oguri T; Kaimori M; Watanabe K; Kobayashi Y; Uchida H; Katayama Y; Sugimoto K; Tashiro H; Kanno H; Yasujima M; Itoh K; Suwabe A; Obata R; Okada M; Kobayashi S; Tsuzimura M; Itoh A; Sumitomo M; Taminato T; Negayama K; Baba H; Makino H; Murase M; Miyamoto H; Minakuchi K; Ishigo S; Takii M; Horii T; Ono J; Takata T; Yamanaka K; Hamazaki N; Tsutsui T; Okabe H; Tatewaki K; Moro K; Hiramatsu K; Saikawa T; Ichiyama S; Nagasawa Z; Aoki Y; Matsushima T; Niki Y; Hirakata Y; Kohno S; Kuwabara M; Nakagawa K; Kageoka T; Hongo T; Yamane N
    Jpn J Antibiot; 2003 Oct; 56(5):341-64. PubMed ID: 14692376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [An antimicrobial resistance surveillance of gram-positive cocci isolated from 12 teaching hospitals in China in 2009].
    Sun HL; Wang H; Chen MJ; Liu YM; Hu ZD; Liao K; Chu YZ; Lei JE; Zhang B; Yu YS; Hu BJ; Sun ZY; Zhang Z; He QY
    Zhonghua Nei Ke Za Zhi; 2010 Sep; 49(9):735-40. PubMed ID: 21092441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective study using standardized methodology for antimicrobial susceptibility of gram-positive cocci isolated from the Puerto Rico Medical Center.
    Rodríguez JL; Vázquez GJ; Bermúdez M; De Orbeta J; García Y; Rivera Y; Robledo IE
    P R Health Sci J; 2002 Dec; 21(4):343-7. PubMed ID: 12572243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
    Nakashio S; Iwasawa H; Iino S; Shimada J
    Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1990; 36(5):365-72. PubMed ID: 2209169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis.
    Lewin CS; Morrissey I; Smith JT
    J Pharm Pharmacol; 1991 Jul; 43(7):492-4. PubMed ID: 1682462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.
    Gargallo-Viola D; Ferrer S; Tudela E; Robert M; Coll R; Roser R; Guinea J
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3113-21. PubMed ID: 11600365
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
    Li JT; Li Y; Wang J;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
    Thomson KS; Sanders CC
    J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
    Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y
    Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
    Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R
    J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
    Hope R; Chaudhry A; Adkin R; Livermore DM
    Int J Antimicrob Agents; 2013 Mar; 41(3):213-7. PubMed ID: 23298432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
    Wang FD; Liu IM; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.